Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer

Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer have?

Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer has 142 citations in the OpenAlex counts ScholarIQ stores.

When was Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer published?

Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer has 2021 year in the ScholarIQ index.

What is the open-access status of Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer?

Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer has hybrid oa status in the ScholarIQ index.

What is the DOI of Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer?

The DOI for Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer is on the source record.

What is the PMID of Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer?

The PMID for Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer is on the source record.

What is the OpenAlex record for Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer?

The OpenAlex for Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer is on the source record.